Drawing for MILLICENT CONSULTING SERVICES LLC PHARMA | BIOTECH | HEALTHCARE | RESEARCH | DATA | SOLUTIONS

USPTO serial 88710925

MILLICENT CONSULTING SERVICES LLC PHARMA | BIOTECH | HEALTHCARE | RESEARCH | DATA | SOLUTIONS

Reviewed by CopyMark Law Group

Filing date
Status date
Registration date
—
Examiner
TRATOS, MARK STEVEN
Law office
TMO LAW OFFICE 113 - EXAMINING ATTORNEY ASSIGNED

What this means

These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.

Status 602: These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances.

Need help with MILLICENT CONSULTING SERVICES LLC PHARMA | BIOTECH | HEALTHCARE | RESEARCH | DATA | SOLUTIONS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
035Business advisory services in the field of clinical trials; Business consulting and management in the field of clinical trials, namely, clinical data and regulatory submission management on behalf of medical, biopharmaceutical and biotechnology companies to assist them with clinical research, clinical trials and applications for drug approval; Providing independent review of clinical trials for business purposesACTIVEMay 26, 2019
042Clinical research in the field of oncology; Clinical research in the field of hematology; Clinical research in the field of immunooncology; Clinical research in the field of cardiology; Clinical research in the field of neurology; Clinical research in the field of immunology; Clinical research in the field of virology; Clinical research in the field of hepatology; Clinical research in the field of ophthalmology; Consulting services for others in the field of design, planning, and implementation project management of clinical trials; Consulting services for others in the field of design, planning, and implementation project management of clinical research; Consulting services for others in the field of design, planning, and implementation project management of biomedical research; Providing medical and scientific research information in the field of clinical trials; Providing medical and scientific research information in the field of pharmaceuticals and clinical trialsACTIVEMay 26, 2019

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB2): The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.

DateCodeEventWhat it means
Jun 3, 2022MAB2ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 3, 2022MAB2ABANDONMENT NOTICE MAILED - FAILURE TO RESPONDThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Jun 3, 2022ABN2ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSEThe trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time.
Nov 12, 2021GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 2021GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Nov 12, 2021CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Oct 13, 2021RCCKSUSPENSION CHECKED - TO ATTORNEY FOR ACTION—
Mar 29, 2021RCSCREPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED—
Sep 28, 2020GNS3NOTIFICATION OF LETTER OF SUSPENSION E-MAILED—
Sep 28, 2020GNSLLETTER OF SUSPENSION E-MAILED—
Sep 28, 2020CNSLSUSPENSION LETTER WRITTEN—
May 2, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 2, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
May 2, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
Mar 10, 2020GEANNOTIFICATION OF EXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Mar 10, 2020GEAPEXAMINER'S AMENDMENT/PRIORITY ACTION E-MAILED—
Mar 10, 2020EPENCOMBINED EXAMINER'S AMENDMENT/PRIORITY ACTION AUTOMATIC ENTRY—
Mar 10, 2020CPEAEXAMINERS AMENDMENT AND/OR PRIORITY ACTION - COMPLETED—
Mar 3, 2020DOCKASSIGNED TO EXAMINER—
Dec 6, 2019MDSCNOTICE OF DESIGN SEARCH CODE E-MAILED—
Dec 5, 2019NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Dec 4, 2019NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance